Alexandria Venture Investments

Hoofprint Biome is a biotechnology company that develops probiotics and natural enzymes to enhance the sustainability of ruminant livestock production. Their products improve cattle health and digestive care by reducing methane emissions, thereby enabling the livestock industry to adopt more sustainable practices through microbiome engineering.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating disease-driving cells. Utilizing its unique cytotoxicity-targeting chimera platform, the company focuses on creating oncology therapeutics that address not only cancer but also inflammatory and autoimmune diseases. By targeting and eliminating these harmful cells, Solu Therapeutics seeks to enhance treatment efficacy and reduce the associated risks in oncology, ultimately aiming to improve patient outcomes in various medical conditions.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to expedite the development of new crops tailored for future agricultural needs. Utilizing AI-assisted plant breeding methods, Avalo creates non-GMO products that foster natural biodiversity. Its core technology, a discovery engine, can swiftly identify genetic bases of complex traits even in understudied crops, reducing time and cost significantly compared to traditional methods. This enables Avalo to forecast and enhance crop traits like drought tolerance and nutrient density, adapting agriculture to changing climates.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

Autoimmunity BioSolutions is a biotechnology company developing innovative solutions for autoimmune diseases, with a focus on multiple sclerosis. Their core technology involves a next-generation immuno-corrective therapy, tailored to a specific genetic subgroup of autoimmune patients. This therapy aims to restore normal immune function by targeting a specific genetic variant (SNP) driving the autoimmune pathology. The company's platform enables targeted modulation of the immune system, offering potential clients a means to correct immune system dysfunction with precision therapies.

Valora Therapeutics, based in San Diego, California, is a biotechnology company focused on the development of innovative biological drugs. It specializes in engineering chimeric antibodies, which are designed to harness the body's immune system to fight cancer and other diseases. The company operates at the pre-clinical stage, working to unlock new mechanisms of immune signaling and activity, with the aim of providing transformative therapies to the healthcare industry.

Jupiter Bioventures is a venture builder company dedicated to de-risking early-stage therapeutic projects. It operates by evaluating opportunities through a specific set of investment criteria and providing initial seed capital to founders. This approach enables the growth of innovative projects in the biotechnology sector, supporting entrepreneurs as they navigate the challenges of early development. By focusing on early-stage initiatives, Jupiter Bioventures aims to foster advancements in therapeutic solutions while minimizing the inherent risks associated with new ventures.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) aimed at transforming cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable, targeted ADC therapeutics. This approach allows for enhanced efficacy and safety profiles, offering potential improvements in cancer therapy. CrossBridge Bio's commitment to innovation in ADC therapeutics positions it as a key player in the biotechnology sector, dedicated to advancing treatment options for patients with cancer.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

Archon Bio is a biotechnology company that specializes in engineering proteins to enhance therapeutic outcomes. It focuses on creating self-assembling protein antibody nanomaterials, aiming to improve immune modulation and super agonism of the TNF receptor superfamily. By increasing the size and valency of off-the-shelf antibodies, Archon seeks to induce stronger responses, thereby advancing regenerative medicine and cancer treatment.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics aimed at addressing significant and unmet needs in central nervous system disorders. By leveraging precision medicine, Leal Therapeutics seeks to provide effective treatment options for patients suffering from various neurological conditions. The company's commitment to advancing therapeutic solutions is reflected in its dedication to improving patient outcomes through targeted interventions.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.

Terray Therapeutics, founded in 2018 and based in Pasadena, California, is a biotechnology company dedicated to advancing drug discovery for intractable diseases. It operates a unique platform that combines experimentation and computation to efficiently explore chemical space, generating precise data through rapid design-make-test-analyze cycles. The company employs artificial intelligence, synthetic chemistry, automation, and nanotechnology to create comprehensive datasets using ultra-dense microarray technology. These datasets systematically map biochemical interactions between small molecules and disease targets, enabling iterative cycles of virtual molecular design and experimentation that guide AI and machine learning models for predictive insights in drug discovery.

Judo Bio is a biotechnology company focused on developing precision therapeutics that target specific cell populations to treat genetic diseases. Utilizing an innovative receptor targeting approach, Judo Bio is building a pipeline of treatments designed to address both common and rare diseases. Currently, the company is operating in stealth mode, indicating a period of research and development prior to a public launch or disclosure of its initiatives.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Radiant Biotherapeutics is an innovative biotechnology company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by creating multi-functional biologics designed to address challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging the principles of avidity and enhanced binding power, Radiant Biotherapeutics enables healthcare professionals to deliver potent therapies that have the potential to transform treatment outcomes for patients. The company's commitment to pioneering these advanced therapeutics positions it at the forefront of the biotherapeutics field, striving to unlock new avenues for patient care.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the obstacles posed by tumors. Through its innovative approach, OverT Bio aims to enhance the effectiveness and durability of immunotherapies, contributing to advancements in cancer identification and treatment within the healthcare sector.

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.

Enlaza Therapeutics is a biotechnology research company founded in 2020 and headquartered in La Jolla, California. The company focuses on developing novel protein therapeutics aimed at providing more effective and safer treatment options for patients. Utilizing advanced synthetic biology technology, Enlaza Therapeutics specializes in site-specific covalent coupling driven by drug binding. This innovative approach allows the development of first-in-class covalent biologics that have the potential to deliver enhanced efficacy and improved safety profiles compared to traditional therapies.

5Metis is an innovative agricultural company focused on enhancing crop health through advanced discovery methods. Formed from the integration of Boragen and AgriMetis, the company specializes in boron-based small molecule discovery alongside synthetic biology to identify new modes of action for crop protection. By leveraging these technologies, 5Metis aims to provide valuable solutions that support growers and improve agricultural practices. The company is dedicated to advancing the agricultural industry by delivering effective services that enhance crop health and protection, ultimately benefiting farmers and their yields.

Clasp Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapeutics. The company has created a platform that aims to enhance the ability of the immune system to recognize and eliminate challenging tumors associated with common driver mutations, irrespective of tumor type. By leveraging precision medicine, Clasp Therapeutics seeks to identify cancer-specific markers that allow for the targeted destruction of tumor cells, thereby improving treatment outcomes for patients with difficult-to-treat cancers.

Umaro Foods focuses on creating a sustainable plant-based protein derived from ocean-farmed seaweed. The company aims to provide an alternative to traditional animal products by offering nutritious and flavorful food options, including crispy and umami-rich bacon alternatives. By leveraging seaweed farming, Umaro seeks to promote a more humane treatment of animals while also supporting environmental sustainability. The innovative approach positions seaweed as a viable and scalable source of protein, which can surpass traditional soy production, contributing to a thriving planet.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Elo Life Systems is a biotechnology company dedicated to enhancing human health and wellness through innovative food solutions. The company aims to bridge the gap between food, agriculture, and health by employing precision gene editing and breeding technologies, genomics, and data analytics. Through partnerships with stakeholders across the food systems value chain, Elo focuses on improving agricultural productivity, meeting nutritional demands, and addressing food security challenges. By replacing sugar and artificial sweeteners with healthier alternatives, Elo Life Systems empowers individuals to enjoy their favorite foods while promoting healthier lifestyles.

Tr1x is a biotechnology company focused on developing cellular therapies for the treatment of autoimmune disorders. Utilizing an exclusive platform, Tr1x creates innovative cell therapy products aimed at recalibrating the immune system to restore balance and promote long-term tolerance in patients. The company leverages advancements in genetic engineering and T-cell biology to design scalable and effective curative solutions that target inflammation and autoimmunity. Through its work, Tr1x aims to provide transformative therapies that address the needs of individuals suffering from autoimmune and inflammatory diseases.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

CIBO Technologies, Inc. is a company that specializes in developing software products to model and simulate agricultural ecosystems, aimed at enhancing sustainable practices in agriculture. Its key offerings include Continuum DB, a distributed database for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; WhetherRain, an integrated weather simulation tool; and DirtPatch, a platform for environmental reconstruction. Additionally, CIBO provides TerraFarm for planetary-scale simulations and the Land Intelligence platform, which generates insights on agricultural parcels while offering access to publicly available data for various stakeholders in the agriculture sector. The company's solutions are designed to support a wide range of crops and serve multiple industries, including farm services, agribusiness, and sustainability. Founded in 2014 and based in Cambridge, Massachusetts, with additional offices in Saint Louis, East Lansing, and Minneapolis, CIBO aims to advance food system resilience and improve grower outcomes in the face of climate change.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Ability Biologics is a biotechnology company focused on developing innovative immune-modulating biotherapeutics aimed at addressing significant unmet medical needs in patients suffering from cancer and autoimmune diseases. The company leverages a platform that employs advanced artificial intelligence to analyze a vast database of antigen-antibody interactions. This technology enables the creation of tailored and effective antibody therapeutics designed to provide healthcare professionals with potent treatment options for conditions that currently lack adequate solutions. Through its commitment to addressing these critical health challenges, Ability Biologics seeks to enhance patient outcomes and advance the field of immunotherapy.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Georgiamune is a biotechnology company specializing in immunotherapy for cancer treatment. It develops advanced immunotherapeutic and homeostatic therapies aimed at enhancing the body's natural defenses against cancer, with the goal of improving patient recovery times.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating disease-driving cells. Utilizing its unique cytotoxicity-targeting chimera platform, the company focuses on creating oncology therapeutics that address not only cancer but also inflammatory and autoimmune diseases. By targeting and eliminating these harmful cells, Solu Therapeutics seeks to enhance treatment efficacy and reduce the associated risks in oncology, ultimately aiming to improve patient outcomes in various medical conditions.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

Bitterroot Bio is a biotechnology company focused on developing innovative therapies for cardiovascular disease by harnessing the immune system's natural capabilities. The company conducts research to uncover the essential roles of immune cells and immune modulators in the onset and progression of cardiovascular conditions. By leveraging immunotherapy, Bitterroot Bio aims to create and deliver novel medicines that can significantly improve treatment options for patients suffering from these diseases, thereby transforming the landscape of cardiovascular care.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Radiant Biotherapeutics is an innovative biotechnology company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by creating multi-functional biologics designed to address challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging the principles of avidity and enhanced binding power, Radiant Biotherapeutics enables healthcare professionals to deliver potent therapies that have the potential to transform treatment outcomes for patients. The company's commitment to pioneering these advanced therapeutics positions it at the forefront of the biotherapeutics field, striving to unlock new avenues for patient care.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Function Oncology is a precision medicine company focused on transforming cancer treatment through its innovative CRISPR-powered personalized functional genomics platform. This platform enables the identification of therapeutic opportunities tailored to individual patients, allowing for a deeper understanding of cancer at a patient-specific level. By leveraging advanced genomic techniques, Function Oncology aims to develop targeted cancer therapies that address the unique characteristics of each patient's disease, ultimately advancing the future of cancer care.

Tiamat Sciences is a start-up focused on producing affordable, animal-free growth factors and biomolecules through innovative plant-based bioreactors. Utilizing proprietary technology, the company manufactures a diverse array of high-value proteins, including antigens and growth factors, achieving significant cost reductions—up to 10 times lower than traditional methods, with potential for further reductions at scale. This technology not only enhances production efficiency but also supports ecological sustainability by providing plant-based alternatives to animal-derived materials in the pharmaceutical industry. Tiamat's approach increases the safety and speed of production, positioning it as a strategic partner for scaling operations in burgeoning sectors such as cellular agriculture and gene therapy. The low capital investment required for facility setup makes Tiamat an attractive option in a market poised for substantial growth.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By investigating the unique characteristics of the bat genome, the company aims to identify and develop therapeutics for various diseases. Leveraging insights gained from bat biology, Paratus Sciences seeks to enable patients to combat and potentially cure the diseases they face. Through its innovative approach, the company aspires to contribute significantly to advancements in medical treatments and public health.

Garuda Therapeutics is a biotechnology company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening blood, bone marrow, immune, and metabolic diseases. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants. Utilizing advanced technologies, including zebrafish, mice, and human-induced pluripotent stem cells, Garuda Therapeutics conducts research to clone and analyze novel genes and mechanisms critical for blood formation. This innovative approach is designed to provide patients with consistent, durable, and HLA-compatible transgene-free blood stem cell therapies, offering rapid and broad access to life-saving treatments.

IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Melonfrost is a biotechnology company located in Brooklyn, New York. It specializes in developing a clinical research platform aimed at optimizing biological strains by addressing operational bottlenecks. The company employs a combination of machine learning, proprietary artificial intelligence, and advanced hardware to facilitate real-time cell evolution. This innovative approach enables Melonfrost to explore the biological landscape effectively and implement advancements in robotics, sensing, fluidics, and environmental control. By streamlining scientific labor processes, Melonfrost significantly reduces the time required to bring bioproducts to market, thereby enhancing the efficiency and effectiveness of biotechnological innovations.

Dantari is a biotechnology company focused on developing innovative treatments for serious diseases, including cancer and disorders of the central nervous system. The company has created a pharmaceutical platform that facilitates the research and development of both small and large molecule therapeutics capable of crossing the blood-brain barrier. This advancement allows for the rapid progression of therapies aimed at delivering meaningful medical improvements to patients' lives. Additionally, Dantari's novel antibody-drug conjugate platform features a higher drug-to-antibody ratio compared to traditional approaches, along with the ability to release therapeutic payloads in a tunable manner. This technology enhances the efficacy and therapeutic potential of its medicines, ultimately aiming to improve patient health outcomes.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. It employs a combination of human genetics, functional genomics, and advanced microscopy techniques to identify novel targets and therapeutics. The company utilizes viral tools and platforms for screening targets that influence the progression of neurodegenerative conditions, alongside functional genetic screening and multi-omics methods. By integrating these state-of-the-art approaches, Cajal Neuroscience aims to advance precision medicine, ultimately enabling healthcare professionals to improve treatment outcomes for patients suffering from neurodegenerative disorders.

Rezo Therapeutics is a biotechnology company that focuses on pioneering the integrated mapping of disease networks to develop precision therapeutics. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo combines proteomics, genetics, structural biology, chemistry, and bioinformatics to create comprehensive maps of molecular disease networks. This innovative approach enables oncologists and researchers to identify novel targets and therapies with greater clarity and precision than traditional drug discovery methods. Initially concentrating on oncology, Rezo Therapeutics plans to expand its therapeutic focus through collaborations and partnerships, aiming to address a wide range of diseases.

Haystack Oncology is an oncology company that specializes in advanced liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. The company utilizes state-of-the-art circulating tumor DNA detection methods to enhance the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. By analyzing tumor-specific markers in blood samples, Haystack Oncology's technology provides high sensitivity for early detection of recurrent disease, thereby enabling healthcare teams to effectively manage cancer treatment. The company's innovative approach seeks to transform how cancer is monitored and treated, ultimately benefiting patients through improved diagnostic accuracy and treatment effectiveness.

Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious illnesses. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance the discovery process. This innovative approach allows for deeper probing of the proteome to identify new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Tavros Therapeutics is a biotechnology company based in Durham, North Carolina, focused on discovering and developing therapies for cancer. Founded in 2019, the company aims to advance oncology treatments by identifying vulnerabilities within tumors. This approach allows for targeted drug combinations, potentially improving outcomes for patients with oncological diseases.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Ozette Technologies focuses on digitizing biological data using machine learning to provide a comprehensive understanding of the human immune system. The company has developed a single-cell immune monitoring platform that facilitates cell discovery and annotation, allowing for deeper insights into immune responses. By employing AI-driven computational analysis, Ozette enhances the discovery and development of therapies and diagnostics, enabling scientists and healthcare providers to navigate the complexities of the immune system in both health and disease. This innovative approach aims to improve patient outcomes through more effective therapeutic strategies.

Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company aims to revolutionize cancer immunotherapies by identifying the safest and most effective targets for treatment. Utilizing a platform-based cell therapy approach, Cartography employs single-cell analysis to discover novel CAR-T targets. This methodology empowers clients to enhance their molecular biology and computational methods, facilitating the advancement of innovative cancer immunotherapies. By prioritizing precision and safety, Cartography Biosciences is dedicated to transforming the landscape of cancer treatment.

DEM BioPharma is an immuno-oncology company focused on developing innovative therapies to combat cancer by harnessing the innate immune system. The company is pioneering a platform dedicated to creating next-generation macrophage immunotherapies, which aim to activate macrophages and immune phagocytes to effectively target and eliminate tumors. By researching and targeting specific signals on both cancer cells and macrophages, DEM BioPharma seeks to provide healthcare researchers with advanced treatment options that enhance the body's ability to fight cancer.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Pheast Therapeutics is a cancer immunotherapy company established in 2020 and based in Palo Alto, California. The company is dedicated to developing innovative checkpoint therapies aimed at utilizing the innate immune system to combat cancer. Specifically, Pheast Therapeutics focuses on blocking macrophage checkpoints, which enhances the ability of macrophages to effectively eliminate tumors, particularly in ovarian and breast cancers. By targeting these immune checkpoints, Pheast Therapeutics aims to improve patient survival rates in oncology.

Umaro Foods focuses on creating a sustainable plant-based protein derived from ocean-farmed seaweed. The company aims to provide an alternative to traditional animal products by offering nutritious and flavorful food options, including crispy and umami-rich bacon alternatives. By leveraging seaweed farming, Umaro seeks to promote a more humane treatment of animals while also supporting environmental sustainability. The innovative approach positions seaweed as a viable and scalable source of protein, which can surpass traditional soy production, contributing to a thriving planet.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Eclipse BioInnovations is a prominent RNA genomics company established in 2017, leveraging innovative technology developed at the University of California, San Diego. The company specializes in advanced RNA genomics platforms aimed at enhancing RNA medicines and scientific research. Its founders introduced eCLIP, a highly efficient CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse BioInnovations offers a comprehensive suite of RNA genomics technologies, including eCLIP-RBP for mapping RNA binding proteins, miR-eCLIP for analyzing the miR-interactome, m6A-eCLIP for studying RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for streamlining CRISPR library preparation. These products are available as services and kits for biopharmaceutical companies and academic researchers and can be customized to meet specific client needs. By providing these specialized genomics-based products and services, Eclipse BioInnovations empowers scientists to accelerate their research and develop effective therapies for various human diseases.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.

Terray Therapeutics, founded in 2018 and based in Pasadena, California, is a biotechnology company dedicated to advancing drug discovery for intractable diseases. It operates a unique platform that combines experimentation and computation to efficiently explore chemical space, generating precise data through rapid design-make-test-analyze cycles. The company employs artificial intelligence, synthetic chemistry, automation, and nanotechnology to create comprehensive datasets using ultra-dense microarray technology. These datasets systematically map biochemical interactions between small molecules and disease targets, enabling iterative cycles of virtual molecular design and experimentation that guide AI and machine learning models for predictive insights in drug discovery.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to expedite the development of new crops tailored for future agricultural needs. Utilizing AI-assisted plant breeding methods, Avalo creates non-GMO products that foster natural biodiversity. Its core technology, a discovery engine, can swiftly identify genetic bases of complex traits even in understudied crops, reducing time and cost significantly compared to traditional methods. This enables Avalo to forecast and enhance crop traits like drought tolerance and nutrient density, adapting agriculture to changing climates.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on discovering and developing innovative therapies for severe liver diseases. Founded in 2016, Ambys aims to transform the lives of individuals suffering from liver conditions by creating advanced gene, drug, and cell therapies. The company is dedicated to restoring liver function, halting the progression of liver disease, and addressing the serious complications associated with liver failure. Through its regenerative medical therapies, Ambys seeks to provide relief to patients with chronic liver diseases, ultimately improving their quality of life.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

NextVivo is a biotech company focused on advancing drug development through its innovative immune organoid technology platform. The company aims to create safer and more effective therapies by utilizing immune-competent, human-derived models. Its technology involves the use of miniature 3D cell cultures, known as organoids, which accurately replicate the composition, structure, and function of human tissue. This unique approach allows for the modeling of both humoral and cellular immune responses outside the human body. By enabling the testing of pre-clinical candidates on ex vivo human tissue models, NextVivo facilitates the identification of the most promising therapies for clinical development, thereby enhancing the drug discovery process.

Fountain Therapeutics, established in 2018 and headquartered in San Francisco, specializes in developing treatments for age-related diseases using cellular models and an AI-based platform for target discovery. The company aims to recreate aging's complex hallmarks in lab dishes, combining this model with artificial intelligence and computer vision to identify novel targets unbiasedly.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Nitrase Therapeutics is a biopharmaceutical company focused on developing innovative therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create treatments that may slow or halt the progression of this condition. The company leverages its proprietary platform, which is based on the biochemical modification of proteins through nitration, to identify nitro-substrates and their relevance in various diseases. This approach not only addresses Parkinson's but also positions Nitrase to expand its research into other therapeutic indications, with the goal of offering novel medicines that target this specific enzyme pathway.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Soli Organic is an indoor farming startup that specializes in providing fresh organic culinary herbs to grocery stores, ensuring a year-round supply for consumers. The company's offerings include a variety of herbs such as basil, rosemary, lime leaves, chives, and arugula, all cultivated as living plants with fresh-cut leaves. Soli Organic focuses on delivering healthy and flavorful products that promote local consumption and enhance culinary experiences. By growing these herbs regionally, the company aims to make fresh organic options accessible to millions, thereby contributing to a more flavorful and sustainable food culture.

Immunai Inc. is a biotechnology company that specializes in developing an artificial intelligence-based immune profiling platform aimed at enhancing drug development and improving disease detection, diagnosis, and treatment. The company utilizes single-cell genomics and machine learning algorithms to conduct high-resolution profiling of the immune system, generating valuable biological insights that facilitate research and development. Immunai's platform focuses on biomarker discovery, enabling the identification of how immune cells respond to various conditions, and supports the development of therapies for oncology and autoimmune disorders. Established in 2018 and headquartered in New York City, Immunai also maintains offices in San Francisco and Tel Aviv, collaborating with academic institutions, biopharmaceutical firms, and biotechnology companies to advance its mission of mapping the immune system and its functions.

Mozart Therapeutics is a biotechnology startup dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in creating disease-modifying CD8 T cell modulators, leveraging a unique regulatory CD8 T cell network to target a specific subset of T lymphocytes. These modulators aim to restore immune balance and mitigate the damage caused by autoreactive and pathogenic immune responses. By focusing on first-in-class CD8 Treg modulators, Mozart Therapeutics seeks to delay the onset and improve the management of various autoimmune disorders, thereby providing healthcare professionals with advanced treatment options for their patients.

Crop Enhancement LLC is an early-stage specialty materials company based in San Jose, California, founded in 2011. The company focuses on developing innovative anchoring and controlled-release formulation technologies for agricultural chemicals. Its advanced agrochemical formulations utilize environmentally friendly chemistry to enhance crop yields and profitability while minimizing the reliance on synthetic pesticides. Crop Enhancement's products include proprietary films that modify plant surfaces, improving resistance to pests and diseases. This approach not only supports sustainable farming practices but also enables precise delivery of active ingredients and fertilizers, ultimately benefiting growers through increased efficiency and reduced chemical use.

BIOMILQ is a women-owned start-up based in Durham, North Carolina, founded in 2020. The company specializes in producing nutritionally equivalent breastmilk using cultured human mammary cells. By leveraging a unique biomanufacturing platform, BIOMILQ aims to create bioauthentic human milk ingredients that support early-life nutrition. Its products are designed to provide a sustainable and nutritious alternative for mothers and caregivers, promoting immune, gut, and neurological development in infants. Through its patented technology, BIOMILQ seeks to empower families with options that mirror the benefits of natural breastmilk, enhancing infant health and nutrition.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focusing on the creation and commercialization of human tissue-based products for regenerative medicine and vascular surgery. Established in 2004, the company specializes in developing acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to prevent rejection. These engineered tissues are designed for use as vascular grafts, providing solutions for patients requiring vascular repair or replacement. Humacyte aims to deliver universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while advancing the field of medicine.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapeutics for Long QT Syndrome and other arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, as well as atrial fibrillation and treatment-resistant cancers. Thryv Therapeutics specializes in creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to provide therapies that can significantly reduce the risk of sudden cardiac death and enhance the quality of life for patients affected by these serious conditions.